Genetic variants can affect the response to GLP-1 agonists for weight loss
The average age of respondents was 38
Emphasizing the overlap and differences between bench and bedside research findings, we examine the translational potential of proposed metabolic biomarkers for improving TBI management and as therapeutic targets
Since then, several GLP-1s for obesity have been approved for new indications, such as secondary cardiovascular risk reduction (Wegovy), sleep apnea (Zepbound) and metabolic dysfunction-associated steatohepatitis, or MASH (Wegovy)
8 The authors attributed this adverse outcome to the large and rapid fall in hemoglobin A1c levels during the initial 16 weeks of the trial 9,10
Current treatment options for MAFLD focus primarily on lifestyle interventions, such as dietary changes and physical activity, which pose challenges for long-term adherence owing to the difficulty in maintaining these lifestyle changes over time
/assets/production/practices/bb098bde1976b73281d3b963c3dfa64815de4cfc/images/2780379.jpeg)
:format(webp))
